Enliven Therapeutics, INC 8-K filings

Enliven Therapeutics has priced an upsized public offering of common stock and pre-funded warrants to raise approximately $400 million in gross proceeds.

Enliven Therapeutics announced updated positive Phase 1 data for its CML drug ELVN-001, showing encouraging efficacy and a favorable safety profile, and confirmed alignment with the FDA on Phase 3 trial design.

Enliven Therapeutics announced positive initial Phase 1b data for ELVN-001 in CML patients and a strong cash position extending into the first half of 2029.

Enliven Therapeutics appoints biopharma veteran Scott Garland to its Board of Directors, signaling a strategic shift towards late-stage development and commercialization of its lead asset, ELVN-001.

Enliven Therapeutics announced the appointment of Rick Fair as its new President and CEO, effective December 11, 2025, with co-founder Samuel Kintz transitioning to Head of Pipeline.

Enliven Therapeutics announced its third-quarter 2025 financial results and provided a business update, highlighting progress in its ELVN-001 CML trial and a strong cash position.

Enliven Therapeutics reports strong Q3 2025 financial results, advances its lead CML drug ELVN-001 towards Phase 3, and maintains a robust cash position.

Enliven Therapeutics announced positive Phase 1 clinical trial data for ELVN-001 in CML and a strengthened balance sheet extending cash runway into the first half of 2029.

Enliven Therapeutics, Inc. held its Annual Meeting of Stockholders on June 24, 2025, successfully electing three Class II Directors and ratifying Deloitte & Touche LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025.

Enliven Therapeutics, a clinical-stage biopharmaceutical company, has successfully priced a public offering of common stock and pre-funded warrants, expecting to raise approximately $216.1 million in net proceeds.

Enliven Therapeutics, Inc. announced updated positive data from its Phase 1 ENABLE clinical trial for ELVN-001 in chronic myeloid leukemia (CML) patients, demonstrating favorable efficacy and safety profiles, particularly in heavily pretreated populations.

Enliven Therapeutics reports promising early clinical trial results for ELVN-001 in CML patients and anticipates a pivotal trial in 2026, while also exploring strategic options for ELVN-002.

Enliven Therapeutics reports its financial results for Q4 and full year 2024, highlighting pipeline progress and a strong cash position.

Enliven Therapeutics reported positive Phase 1 clinical trial data for ELVN-001 in CML, progress in ELVN-002 trials, and a strong cash balance of $292 million.

Enliven Therapeutics announced the dosing of the first patients in Phase 1b and 1a clinical trials for their lead programs, ELVN-001 and ELVN-002, respectively, along with a strong cash position.

Enliven Therapeutics' stockholders approved an increase in shares for the equity incentive plan and an amendment to the certificate of incorporation limiting officer liability at the 2024 Annual Meeting.

Enliven Therapeutics has appointed Dr. Lori Kunkel to its Nominating and Corporate Governance Committee, effective immediately.

Enliven Therapeutics reported positive Phase 1 clinical trial data for ELVN-001 in CML, a strong cash position, and secured $90 million in PIPE financing.

Enliven Therapeutics reports promising initial results from its Phase 1 trial of ELVN-001, showing a 44% major molecular response rate in heavily pre-treated CML patients.

Enliven Therapeutics has appointed Dr. Lori Kunkel, a seasoned oncology and immunology expert, to its Board of Directors, effective April 8, 2024.

Enliven Therapeutics has successfully raised approximately $90 million through a private placement to fund its clinical programs and extend its cash runway into late 2026.

Enliven Therapeutics announced its fourth quarter and full year 2023 financial results, along with updates on its clinical programs, including expected initial data readouts for ELVN-001 and ELVN-002.